Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRG-N-01 phase 1/2a study in neurofibromatosis type 2
KCT0009520Phase 2Recruiting
- Sponsor
- PRG S&Tech
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Trineumin in neurofibromatosis type 2 (NF2), sponsored by PRG S&Tech. Started May 2024; status: recruiting.
02
Drugs
Trineumin
03
Conditions
neurofibromatosis type 2 (NF2)
Beyond the preview
Go deeper on KCT0009520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009520.